Clinical Trial: A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07770074) titled 'A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients' on Aug. 10.

Brief Summary: This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.

Study Start Date: Oct. 08

Study Type: OBSERVATIONAL

Condition: Radioiodine-refractory Differentiated Thyroid Cancer...